AlphAIalphai — Financial news for AI agents
StockOTC · US · USDHealthcare · Drug Manufacturers - Specialty & Generic

$MCUJF

MEDICURE INC

Insider trades
Price · $MCUJFvia TradingView
AI sentiment · 7d1 articles
AUG 9net (bullish − bearish)AUG 15
Bullish
0
Neutral
0
Bearish
1
Insider · 30dAll trades →

No SEC Form 4 filings for $MCUJF in the last 30 days.

See all $MCUJF insider activity →
Top stories · $MCUJFMore →
AUG 14·finanznachrichten.deMed

Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call

Medicure Inc. (TSXV:MPH, OTC Pink:MCUJF) reported Q2 2026 results for the quarter ended June 30, 2026. Total net revenue rose to C$7.4M from C$6.7M, driven by ZYPITAMAG (C$2.1M vs C$1.7M) and pharmacy segment revenue (C$5.9M vs C$4.2M). AGGRASTAT fell to C$661K. Net loss was C$1.4M (C$0.14/share). Cash was C$1.8M. Conference call set for Aug 17, 2026.

JUL 3·finanznachrichten.de

Medicure, Inc.: Medicure Announces CFO Change

Medicure Inc. (TSXV:MPH; OTC PINK:MCUJF) said CFO Haaris Uddin resigned effective July 24, 2026. James Kinley, previously CFO (2011–2021) and a board member, was named interim CFO and will take over when Uddin departs. The company did not cite financial figures.

MCUJF sentiment & insider activity

Over the past 7 days, alphai's AI scored 1 news story mentioning MCUJF (MEDICURE INC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

Recent MCUJF coverage spans earnings and financial news.

What's driving MCUJF

alphai scores every news story that mentions MCUJF with an AI model for sentiment and relevance, and aggregates insider trades from MEDICURE INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $MCUJF

Score
AUG 14$MCUJFMedfinanznachrichten.de

Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call

Medicure Inc. (TSXV:MPH, OTC Pink:MCUJF) reported Q2 2026 results for the quarter ended June 30, 2026. Total net revenue rose to C$7.4M from C$6.7M, driven by ZYPITAMAG (C$2.1M vs C$1.7M) and pharmacy segment revenue (C$5.9M vs C$4.2M). AGGRASTAT fell to C$661K. Net loss was C$1.4M (C$0.14/share). Cash was C$1.8M. Conference call set for Aug 17, 2026.

6 min read

Related tickers

More in Drug Manufacturers - Specialty & Generic